Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART

Study Identifier
M01-287
CT.gov Identifier
NCT00038532
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Human Immunodeficiency Virus (HIV)
    • Study Drug
  • Amprenavir/ritonavir
  • Saquinavir/ritonavir
  • Efavirenz
    • Phase
    CSR.ORG
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    Inclusion: - Remain on present anti-HIV drugs during screening until a new regimen is started. - Have a viral load of at least 1,000 copies/ml on the 2 most recent tests after at least 24 weeks of lopinavir/ritonavir and while still on it. - Have an HIV which shows reduced susceptibility to lopinavir. - Are at least 18 years old. - Are not presently ill. - Have not been treated for an opportunistic infection within 30 days of screening. - Agree not to take certain drugs and agree to inform and get permission from the doctor before taking any medicines, over the counter medicines, herbal medicines, alcohol or recreational drugs. - Agree to use an accepted barrier method of birth control. Exclusion: - Female subject is pregnant or lactating. - Have taken any protease inhibitor other than lopinavir/ritonavir for more that two weeks. - Are taking chemotherapy. - Have a medical problem with their pancreas. - Have been screened for this study within the past 12 weeks. - Appear to be unsuitable in the opinion of the doctor.

    Protocol Summary

    The purpose of this study is to study amprenavir/ritonavir, saquinavir/ritonavir or efavirenz

    in HIV-infected patients following failure with Kaletra (ABT-378/ritonavir) as their first

    protease inhibitor based HAART.

    Study Locations

    Location
    Status
    Location
    Phoenix Body Positive, Inc.
    Phoenix,, Arizona, United States, 85006
    Status
    Not applicable
    Location
    Paul J. Cimoch, M.D.
    Fountain Valley, California, United States, 92780
    Status
    Not applicable
    Location
    AIDS Health Care Foundation - Research Center
    Los Angeles, California, United States, 90027
    Status
    Not applicable
    Location
    Tower Infectious Diseases Medical Associates
    Los Angeles, California, United States, 90048
    Status
    Not applicable
    Location
    20th Avenue Medical Center Kaiser Permanente
    Denver, Colorado, United States, 80205
    Status
    Not applicable
    Location
    University of Colorado Health Sciences Center
    Denver, Colorado, United States, 80262
    Status
    Not applicable
    Showing {first} - {last} of {total} Results